Mepivacaine – Kodiac biolabs

Plain-language summaryIntrigue 45 / 100

Mepivacaine (Carbocaine, Polocaine) is the methyl-substituted parent of the pipecoloxylidide family that includes bupivacaine and ropivacaine. Introduced in the late 1950s by Bo af Ekenstam at AB Bofors. The methyl substituent on the piperidine nitrogen makes mepivacaine the shortest-acting member of its family, with onset in 3 to 5 minutes and duration of 2 to 3 hours. Two niches in current practice: dental anesthesia (the 3 percent plain solution avoids epinephrine when the vasoconstrictor is contraindicated, and the duration matches typical procedure length), and ambulatory orthopedic spinal anesthesia where shorter duration than bupivacaine permits earlier ambulation. Sold as a racemate. Cardiotoxicity is intermediate between lidocaine and bupivacaine. Lipid emulsion rescue applies as for any local anesthetic systemic toxicity event. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

34/100

A mature amide local anesthetic with solid clinical utility and no compelling research frontier

Look, mepivacaine does exactly what it says. It blocks voltage-gated sodium channels, it’s been doing that since Bo af Ekenstam synthesized it at AB Bofors in the 1950s, and the clinical literature on it is about as settled as pharmacology gets. That’s the problem from a research standpoint. The mechanism is textbook Na+ channel inactivation, shared by every amide local anesthetic on the shelf. Theres no secondary target, no interesting receptor cross-talk, no emerging biology to chase.

The structural story is genuinely interesting at a chemistry level: the N-methyl substituent on the piperidine ring makes mepivacaine the shortest-acting member of the pipecoloxylidide family, parent to both bupivacaine and ropivacaine. That methyl group reduces lipid solubility relative to bupivacaine, which is why cardiotoxicity sits in a safer intermediate range and why duration tops out at 2 to 3 hours. Understanding that series helped establish how lipophilicity governs duration and toxicity across the class. Good history. Not current research.

Its clinical niches are real and defensible. The 3 percent plain solution occupies a specific slot in dental anesthesia where epinephrine is contraindicated, and the intermediate duration maps well to typical dental procedure length without leaving patients numb for hours. In ambulatory orthopedic spinal anesthesia, mepivacaine’s shorter duration relative to bupivacaine permits earlier ambulation and discharge, which matters operationally. The absence of a para-aminobenzoic acid metabolite separates it from the ester class and makes it usable in patients who react to ester agents. These are practical advantages, not research advantages.

As a bench tool, mepivacaine competes poorly. Investigators studying voltage-gated Na+ channels reach for tetrodotoxin, saxitoxin, or specific Nav subtype blockers with real probe selectivity. Mepivacaine is pan-Nav, low selectivity, widely available, and offers nothing mechanistically that lidocaine or bupivacaine doesn’t also provide. The racemate status means you’re not even getting the cleaner pharmacology that ropivacaine’s S-enantiomer offers in stereochemistry studies.

We dont see a compelling research program that specifically requires mepivacaine. If you’re studying Na+ channel pharmacology, better probes exist. If you’re studying the pipecoloxylidide scaffold, bupivacaine and ropivacaine carry more interesting current literature. Mepivacaine earns its place in the dental chair, not on the bench. Score reflects that honestly: high evidence for an approved, well-characterized agent, but low novelty and mechanism interest that drags the overall into the low thirties where a mature clinical workhorse belongs.

Novelty: 10
Mechanism promise: 12
In-category differentiation: 30
Evidence quality: 75
Translational signal: 65
Research bench value: 25

Rationale Mepivacaine scores low on novelty and mechanism because it’s a 1950s Na+ channel blocker in a mechanistically saturated class; differentiation is modest (a real but narrow niche in dental and ambulatory spinal). Evidence and translational scores are legitimately high for an approved, well-characterized clinical agent, but those gains don’t rescue the overall because there’s no research angle a serious investigator would prioritize over the dozens of more interesting compounds competing for bench time.

Amide local anesthetic (intermediate-acting)

The methyl-substituted pipecoloxylidide parent of bupivacaine and ropivacaine, used in dental and orthopedic regional anesthesia.

Abstract

Mepivacaine (1-methyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; CAS 96-88-8; molecular formula C15H22N2O; molecular weight 246.35) is an amide local anesthetic synthesized by Bo af Ekenstam at AB Bofors in the same pipecoloxylidide series that produced bupivacaine and ropivacaine. The compound was introduced clinically in the late 1950s (Carbocaine, Polocaine) as a successor to lidocaine for dental and short-procedure regional anesthesia. The methyl substituent on the piperidine nitrogen makes mepivacaine the shortest-acting member of the pipecoloxylidide family; lipid solubility and protein binding are intermediate between lidocaine and bupivacaine. Mechanism is voltage-gated sodium channel block. Onset is 3 to 5 minutes for infiltration; duration is 2 to 3 hours, longer with epinephrine. Maximum recommended dose is 5 mg/kg without epinephrine and 7 mg/kg with epinephrine. The principal niches in current practice are dental anesthesia (the 3 percent plain solution avoids epinephrine in patients where the vasoconstrictor is contraindicated, and the intermediate duration matches typical dental procedure length), and ambulatory orthopedic spinal anesthesia where the shorter duration relative to bupivacaine permits earlier ambulation and discharge. Mepivacaine is sold as a racemate. Cardiotoxicity is intermediate between lidocaine and bupivacaine; lipid emulsion rescue applies to LAST. The ester-class procaine and chloroprocaine are alternative short-acting infiltration agents; mepivacaine retains a market niche owing to the absence of the para-aminobenzoic acid metabolite that drives ester allergic reactions.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1312Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.